Moleculin Biotech, Inc. MBRX
At closeNov 3, 2026, 4:02 PM EST
After hours · Nov 3, 4:02 PM ET
- YTD
- +150.76%
- 1 year
- -36.15%
- Market cap
- 8.46M
- EPS (ttm)
- 179.60
- Shares out
- 3.19M
- P/E ratio
- 0.05
- Forward P/E
- -0.29
- YTD return
- +150.76%
- 1-year return
- -36.15%
- Volume
- 12.48K
- Avg volume
- 51.75K
- Open
- 8.27
- Previous close
- 8.32
- Day's range
- 8.27 – 8.42
- 52-week range
- 3.22 – 253.00
- Price target
- 18.00 (+116.9%)
- Earnings date
- Mar 22, 2024
2Y -52.95 (-86.45%)
Key statistics
- Enterprise value
- -4.00M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.52
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -13.24M
- Total cash
- 9.40M
- Total debt
- 390.00K
- Return on equity
- -141.49%
- Short % of float
- 0.71%
- 50-day average
- 2.49
- 200-day average
- 3.26
Analyst view
- Target (low)
- 8.00
- Target (mean)
- 18.00
- Target (high)
- 28.00
- Strong buy2
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
Mar 22, 2024
Expected Mar 22, 2024. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 8, 2024 | Sep 1, 2024 | -2.44 | -2.09 | +0.35 | +14.34% |
| Aug 13, 2024 | Jun 1, 2024 | -2.10 | -2.23 | -0.13 | -6.19% |
| May 10, 2024 | Mar 1, 2024 | -3.59 | -2.02 | +1.57 | +43.73% |
| Mar 22, 2024 | Dec 1, 2023 | -3.00 | — | — | — |
| Nov 13, 2023 | Sep 1, 2023 | -3.15 | -2.85 | +0.30 | +9.52% |
| Aug 11, 2023 | Jun 1, 2023 | -4.20 | -3.00 | +1.20 | +28.57% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 12, 2024 | Maxim Group | main | Buy | Buy |
| Apr 12, 2024 | Roth MKM | main | Buy | Buy |
| Mar 26, 2024 | Maxim Group | main | Buy | Buy |
| Dec 14, 2023 | HC Wainwright & Co. | init | — | Buy |
| Apr 18, 2023 | Roth MKM | main | — | Buy |
| Mar 24, 2023 | Oppenheimer | reit | — | Outperform |
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- moleculin.com
News
Moleculin Biotech Completes Participant Dosing In Part A Of Its Pivotal Phase 2/3 MIRACLE Study Of Annamycin To Treat Adults With Relapsed Or Refractory Acute Myeloid Leukemia 
Moleculin Completes Dosing Patients in Part A of Pivotal MIRACLE Trial; Comprehensive Data Readout on Track for Q1 2027 
12 Health Care Stocks Moving In Tuesday's Intraday Session 
Moleculin Releases Next CEO Corner Segment Highlighting Recent Progress in Annamycin MIRACLE Trial 
Moleculin Biotech Announces 1-For-20 Reverse Stock Split, Effective October 20 
Moleculin Announces Reverse Stock Split 
Moleculin Biotech to Participate in Advances in Oncology Panel at the 2026 Maxim Growth Summit 
Moleculin Biotech Completes Patient Enrollment In Part A Of Its Pivotal Phase 2/3 MIRACLE Study Of Annamycin In Combination With Cytarabine To Treat Adults With Relapsed Or Refractory Acute Myeloid Leukemia 
Moleculin Biotech Completes Enrollment in Part A of Phase 2/3 R/R AML MIRACLE Trial, Keeping Program on Track for Q1 2027 Data Readout 
Moleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular Medicine
Your note
Sign in to keep a note on MBRX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| FOSTER JONATHAN P. | Chief Financial Officer | Conversion of Exercise of derivative security | Jun 20, 2024 | 11,363 |
| GEORGE ROBERT E | Director | Purchase | Dec 25, 2023 | 14,660 |
| KLEMP WALTER V | Chief Executive Officer | Conversion of Exercise of derivative security | Jul 1, 2024 | 57,035 |
| PICKER DONALD H | Officer | Conversion of Exercise of derivative security | Jun 20, 2024 | 8,001 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Armistice Capital, LLC | 9.09% | 290,000 | 501.70K | Sep 29, 2024 |
| Vanguard Group Inc | 2.24% | 71,403 | 123.53K | Sep 29, 2024 |
| LPL Financial LLC | 1.13% | 36,103 | 62.46K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.68% | 21,818 | 37.74K | Sep 29, 2024 |
| Blackrock Inc. | 0.39% | 12,475 | 21.58K | Sep 29, 2024 |
| Renaissance Technologies, LLC | 0.34% | 10,996 | 19.02K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.33% | 42,468 | 73.47K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.95% | 30,314 | 52.44K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.46% | 14,790 | 25.59K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.10% | 3,218 | 5.57K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.06% | 2,055 | 3.56K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.03% | 1,039 | 1.80K | Oct 30, 2024 |